KR970702253A - 아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine) - Google Patents
아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine)Info
- Publication number
- KR970702253A KR970702253A KR1019960705560A KR19960705560A KR970702253A KR 970702253 A KR970702253 A KR 970702253A KR 1019960705560 A KR1019960705560 A KR 1019960705560A KR 19960705560 A KR19960705560 A KR 19960705560A KR 970702253 A KR970702253 A KR 970702253A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- amino
- phenyl
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
본 발명은 각종 악성종양의 치료에 유용한 하기 화학식(1)로 표시되는 아미노스틸바졸 유도체 또는 그 수화물 및 그 염에 관한 것이다:
식 중, R1및 R2는 각각 수소 등을 나타내고; R3, R4, R13및 R4는 각각 수소, C1-C3아실, 할로겐, 히드록시 등을 나타내고; R5는 수소, 히드록실화된 C1-C3알킬 등을 나타내고; R6는 C1-C3알콕시-치환된 벤젠설포닐 등을 나타내고; 고리 Y는 페닐 등을 나타내고; 고리 Z는 4-피리딜 및 그것의 옥사이드등을 나타낸다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 화학식(1)로 표시되는 화합물 또는 그 수화물 및 그 염:식 중, R1및 R2는 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼6의 알킬, 탄소수 1∼6의 아실, 시아노 또는 -COOR(R은 수소 또는 탄소수 1∼6의 알킬)을 나타내고, R3, R4, R13및 R14및 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시, 탄소수 1∼6의 할로알콕시, 탄소수 1∼6의 아실, 탄소수 1∼6의 아실옥시, 히드록시, 할로겐, 니트로, 시아노, 아미노, 탄소수 1∼6의 아실아미노, 탄소수 l∼6의 아미노알켈옥시 또는, 알킬 부분의 탄소수가 1∼6의 모르폴리노알킬옥시를 나타내며, 또한, R3과 R13, 또한 R4와 R14가 함께 메틸렌디옥시를 나타낼 수 있고, R5는 ① 수소, ② 할로겐, 아미노, 탄소수 l∼6의 모노알킬아미노, 탄소수 1∼6의 디알킬아미노, 모르폴리노, 탄소수 1∼6의 알콕시 또는 히드록시로 임의 치환되는 탄소수 1∼6의 알킬, ③ 할로겐으로 임의 치환되는 탄소수 2∼6의 알케닐, ④ 탄소수 2∼6의 알키닐 또는 ⑤ 탄소수 1∼6의 아실을 나타내고, R6은 ① 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시 또는할로겐으로 임의 치환되는 탄소수 7∼11의 아로일 또는 ② 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시, 탄소수 1∼6의 할로알콕시, 히드록시, 니트로 또는 할로겐으로 임의 치환되는 탄소수 6∼10의 아릴설포닐을 나타내고, A, B, G, Q 및 X는 동일하거나 또는 상이한 것으로, 각각 N, CH, N-, O 또는 N, -(R7)[(여기서 R7은 탄소수 l∼6의 알킬 또는 탄소수 7∼14의 아릴알킬; E-는 할로겐이온, 염소산이온, 질산이온과 같은 음이온을 나타냄)를 나타내고, 단, A, B, G가 동시에 N인 경우 및 A, B, G, Q, X가 동시에 CH인 경우는 제외되며, Y, Z는 각각 고리를 나타낸다.
- 제1항에 있어서, R1및 R2가 각각 수소이고; R3, R4, R13및 R14가 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼3의 아실, 할로겐 또는 히드록시이고; R5가 수소 또는 히드록시로 치환된 탄소수 1∼3의 알킬이고; R6이 탄소수 1∼3의 알콕시로 치환된 벤젠설포닐이고; Y 고리가 페닐이고; Z 고리는 4-피리딜 또는 그것의 옥사이드인 것을 특징으로 하는 화합물.
- 제1항에 있어서, R1및 R2가 각각 수소이고; R3, R4, R13및 R14가 동일하거나 또는 상이한 것으로, 각각 수소, 아세틸, 불소 또는 히드록시이고; R5가 수소 또는 히드록시로 치환된 에틸이고; R6이 메톡시로 치환된 벤젠설포닐이고; Y 고리가 페닐이고; Z 고리가 4-피리딜인 것을 특징으로 하는 화합물.
- 제1항에 있어서, (E)-4-[2-[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘, (E)-4-[2-[[[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드, (E) -4-[2-[2-[N-(2-히드록시에틸)-N-(p-에톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드, (E)-4-[2-[2-[N-(2-히드록시에틸)-N-[p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 또는 (E)-4-[2-[2-[N-아세틸-N-(p-메톡시페닐)설포닐]아미노]메틸]에테닐]피리던 1-옥사이드 및 그 염으로부터 선택되는 것을 특징으로 하는 화합물.
- 제1항에 있어서, (E)-4-[2-[[[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘, (E)-4-[2-[2-[N-(2-히드록시에틸)-N-[p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드 또는 (E) -4-[2-[2-[N-(2-히드록시에틸)-N-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 및 그염으로 부터 선택되는 것을 특징으로 하는 화합물.
- 제1항 내지 제5항 중 어느 한 항의 화합물 또는 그것의 수화물 또는 그 염을 유효 성분으로 포함하는 약학 조성물.
- 제1항 내지 제5항 중 어느 한 항의 화합물 또는 그것의 수화물 또는 그 염을 유효 성분으로 포함하는 항암제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP94-068252 | 1994-04-06 | ||
JP6825294 | 1994-04-06 | ||
PCT/JP1995/000658 WO1995027699A1 (fr) | 1994-04-06 | 1995-04-05 | Derive d'aminostilbazole et medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970702253A true KR970702253A (ko) | 1997-05-13 |
KR100293867B1 KR100293867B1 (ko) | 2001-09-17 |
Family
ID=13368389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960705560A KR100293867B1 (ko) | 1994-04-06 | 1995-04-05 | 아미노스틸바졸유도체및의약 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5972976A (ko) |
EP (1) | EP0754682B9 (ko) |
JP (1) | JP3080405B2 (ko) |
KR (1) | KR100293867B1 (ko) |
CN (1) | CN1053658C (ko) |
AT (1) | ATE207057T1 (ko) |
CA (1) | CA2187214C (ko) |
DE (1) | DE69523298T2 (ko) |
DK (1) | DK0754682T3 (ko) |
ES (1) | ES2165911T3 (ko) |
PT (1) | PT754682E (ko) |
RU (1) | RU2138482C1 (ko) |
TW (1) | TW308586B (ko) |
WO (1) | WO1995027699A1 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1072688B1 (en) * | 1998-04-15 | 2004-06-30 | Hiroyoshi Hidaka | Method for in vivo detecting a target protein gene by a drug |
EP1079851B1 (en) * | 1998-05-12 | 2007-07-04 | Greenville Hospital System | Use of anti-prolactin agents to treat cancer |
WO2000064875A1 (fr) * | 1999-04-23 | 2000-11-02 | Nippon Shinyaku Co., Ltd. | Procede de pulverisation |
US6521658B1 (en) | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
MXPA02005866A (es) * | 1999-12-14 | 2002-10-23 | Nippon Shinyaku Co Ltd | Derivados de heterociclo y drogas. |
JP2004359545A (ja) * | 2001-03-08 | 2004-12-24 | D Western Therapeutics Institute | 抗癌剤耐性克服剤 |
KR100801121B1 (ko) * | 2001-04-10 | 2008-02-05 | 니뽄 신야쿠 가부시키가이샤 | 만성 관절 류마티즘 치료제 |
EP1382335A4 (en) | 2001-04-26 | 2006-05-24 | Nippon Shinyaku Co Ltd | PHARMACEUTICAL PRODUCTS |
US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
FR2838437B1 (fr) * | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | Procedes de preparation de combretastatines |
EP1547596A4 (en) * | 2002-09-06 | 2008-11-19 | Western Therapeutics Inst Inc | MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF |
WO2006078941A2 (en) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Novel sirtuin activating compounds and methods of use thereof |
WO2007137196A2 (en) * | 2006-05-19 | 2007-11-29 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer compounds and prodrugs thereof |
US20100198262A1 (en) * | 2009-01-30 | 2010-08-05 | Mckinley Laurence M | Axial offset bone fastener system |
US9884842B2 (en) | 2013-04-19 | 2018-02-06 | Bioventures, Llc | Combretastatin analogs |
AU2014363415B2 (en) | 2013-12-13 | 2019-08-29 | Eurochem Agro Gmbh | Fertilizer mixture containing nitrification inhibitor |
CA2940694A1 (en) | 2014-03-31 | 2015-10-08 | Board Of Trustees Of The University Of Arkansas | Disubstituted triazole analogs |
CN112110829B (zh) * | 2019-06-19 | 2023-08-01 | 复旦大学 | 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2790926B2 (ja) * | 1990-08-20 | 1998-08-27 | エーザイ株式会社 | スルホンアミド誘導体 |
EP0472053B1 (en) * | 1990-08-20 | 1998-06-17 | Eisai Co., Ltd. | Sulfonamide derivatives |
JP2692467B2 (ja) * | 1991-12-09 | 1997-12-17 | ダイキン工業株式会社 | 空調制御装置の電力供給装置 |
US5534654A (en) * | 1991-12-10 | 1996-07-09 | Shionogi & Co., Ltd. | Aromatic-sulfonamide-type hydroxamic acid derivative |
-
1995
- 1995-04-05 KR KR1019960705560A patent/KR100293867B1/ko not_active IP Right Cessation
- 1995-04-05 ES ES95914513T patent/ES2165911T3/es not_active Expired - Lifetime
- 1995-04-05 EP EP95914513A patent/EP0754682B9/en not_active Expired - Lifetime
- 1995-04-05 CA CA002187214A patent/CA2187214C/en not_active Expired - Lifetime
- 1995-04-05 JP JP07526235A patent/JP3080405B2/ja not_active Expired - Lifetime
- 1995-04-05 PT PT95914513T patent/PT754682E/pt unknown
- 1995-04-05 WO PCT/JP1995/000658 patent/WO1995027699A1/ja active IP Right Grant
- 1995-04-05 CN CN95192423A patent/CN1053658C/zh not_active Expired - Lifetime
- 1995-04-05 AT AT95914513T patent/ATE207057T1/de active
- 1995-04-05 DE DE69523298T patent/DE69523298T2/de not_active Expired - Lifetime
- 1995-04-05 DK DK95914513T patent/DK0754682T3/da active
- 1995-04-05 US US08/765,131 patent/US5972976A/en not_active Expired - Lifetime
- 1995-04-05 RU RU96121800A patent/RU2138482C1/ru active
- 1995-04-28 TW TW084104225A patent/TW308586B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2187214C (en) | 2002-03-12 |
EP0754682B9 (en) | 2003-09-17 |
CA2187214A1 (en) | 1995-10-19 |
PT754682E (pt) | 2002-03-28 |
CN1145066A (zh) | 1997-03-12 |
DE69523298T2 (de) | 2002-06-27 |
DK0754682T3 (da) | 2002-02-04 |
MX9604540A (es) | 1997-09-30 |
EP0754682A1 (en) | 1997-01-22 |
US5972976A (en) | 1999-10-26 |
KR100293867B1 (ko) | 2001-09-17 |
WO1995027699A1 (fr) | 1995-10-19 |
DE69523298D1 (de) | 2001-11-22 |
TW308586B (ko) | 1997-06-21 |
JP3080405B2 (ja) | 2000-08-28 |
RU2138482C1 (ru) | 1999-09-27 |
EP0754682B1 (en) | 2001-10-17 |
ATE207057T1 (de) | 2001-11-15 |
ES2165911T3 (es) | 2002-04-01 |
CN1053658C (zh) | 2000-06-21 |
EP0754682A4 (en) | 1998-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970702253A (ko) | 아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine) | |
ATE152719T1 (de) | Chinolylbenzofuran derivate als leukotrien- antagonisten | |
NO900991L (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater | |
TR200100300T2 (tr) | Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri | |
DE69930926D1 (de) | Benzolsulfonamid-derivate und ihre anwendung als arzneimittel | |
HUT54149A (en) | Process for producing new 3-brackets open 4-(1-substituted-4-piperazinyl)-butyl brackets closed-4-thiazolidinone derivatives and pharmaceutical compositions comprising such compounds | |
ES2088933T3 (es) | Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene. | |
NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
NL930018I1 (nl) | (Piperidinylalkyl) chinazolinederivaten,werkwijze voor hun bereiding en farmaceutische preparaten die ze bevatten | |
EA200401172A1 (ru) | Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии | |
AU5932294A (en) | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
HUP0300721A2 (hu) | Antibakteriális hatású (amino-piperidino)-kinolinok és aza-izoszter analógjaik, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DK0656353T3 (da) | Aminoquinolinderivater med en virkning mod malariafremkaldere | |
RU96121800A (ru) | Производное аминостильбазола и лекарственный препарат | |
SE0101579D0 (sv) | New compounds | |
DE69231445D1 (de) | Triazole enthaltende antifungizide mittel | |
SE9703378D0 (sv) | New compounds | |
ATE276257T1 (de) | Pyrazinonderivate | |
DK1022276T3 (da) | Epoxysuccinamidderivater | |
CA2281918A1 (en) | Oxazolidines as 5-ht2a-antagonists | |
DE69512208D1 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
ATE195517T1 (de) | Chinolinonderivate und diese enthaltende antiallergische zusammensetzungen | |
ES2165410T3 (es) | Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
DE69600329D1 (de) | Benzothiazol-Derivate | |
ATE215075T1 (de) | Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20130321 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20140319 Year of fee payment: 14 |
|
EXPY | Expiration of term |